For research use only
| Cat No. | ABC-TC0047 |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | Lymphoblast |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Plasma Cell Leukemia |
| Product Code | ARH-77; ARH77 |
Leverage ARH 77 Cell Line for studies on plasma cell leukemia, immunoglobulin G1 synthesis, EBNA expression, and B-cell malignancy mechanisms.
ARH-77 is a human lymphoblastoid tumor cell line established from the peripheral blood of a 33-year-old female diagnosed with plasma cell leukemia. The cells exhibit suspension growth and display a round to irregular morphology typical of malignant plasma cells. ARH-77 synthesizes immunoglobulin G1 with kappa light chains. Notably, the line is positive for Epstein-Barr virus nuclear antigen (EBNA), indicating latent EBV infection, which may contribute to cellular transformation and survival. Cytogenetic analyses reveal complex chromosomal rearrangements, including abnormalities in chromosome 14q32 involving the immunoglobulin heavy chain locus. ARH-77 is frequently used in hematologic malignancy studies, particularly for modeling terminal B-cell differentiation, monoclonal gammopathies, and immune regulation. Tumorigenic potential in vivo has not been reported. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | ARH-77; ARH77 |
| Species | Human |
| Cat.No | ABC-TC0047 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Plasma Cell Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
ARH-77 is a widely used in vitro model for studying plasma cell leukemia, B-cell differentiation, and antibody secretion mechanisms. Its ability to produce IgG1 (kappa light chain) makes it valuable for research into immunoglobulin regulation, light chain-associated pathologies, and multiple myeloma-like conditions. The EBNA positivity enables studies on Epstein-Barr virus-associated oncogenesis in B-lineage malignancies. ARH-77 supports investigations into plasma cell metabolism, cytokine responses, and resistance to immunotherapy. Its utility extends to evaluating monoclonal antibody production, cellular immunophenotyping, and genetic abnormalities common in plasma cell neoplasms. This line is ideal for translational and mechanistic studies in hematologic cancers and immunologic disorders.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
